Alnylam Pharma (ALNY) Tops Q1 EPS by 11c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
EPS Growth %: +403.1%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.64), $0.11 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $177.6 million versus the consensus estimate of $168.74 million.
2021 Financial Guidance
Full year 2021 financial guidance is reiterated and consists of the following:
Combined net product revenues for ONPATTRO, |
|
$610 million - $660 million | |
Net revenues from collaborations and royalties |
| $150 million - $200 million | |
GAAP R&D and SG&A expenses |
| $1,335 million - $1,455 million | |
Non-GAAP R&D and SG&A expenses* |
| $1,175 million - $1,275 million |
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Medtronic completes $550 million Scientia Vascular acquisition
- MIND Technology (MIND) Misses Q1 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
